QazCovid-in

Source: Wikipedia, the free encyclopedia.

QazCovid-in
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Routes of
administration
Intramuscular
Identifiers
DrugBank

QazCovid-in, commercially known as QazVac,[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.[3][4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.[5]

Manufacturing

The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.[6]

The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.

Beginning in June 2021, the vaccine is slated[7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.[8][9] This will allow for a production capacity of 500,000-600,000 doses per month.[10] The contract is still being negotiated,[11] despite earlier claims suggesting that the deal had already been finalized.[12][13]

In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.[14]

History

Clinical trials

In September 2020, QazVac started in Phase I/II clinical trials.[15]

In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.[16][17] It is unclear when the first preliminary results will be published.[18][19]

The administration of the vaccine for the general population began at the end of April 2021.[20] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".[21]

In September 2021, a study was published to EClincicalMedicine, published by The Lancet. The study’s finidings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” [22]

Authorization

Economics

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[citation needed] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.[23]

References

  1. ^ "Kazakhstan: Officials under fire over vaccination failures | Eurasianet". eurasianet.org. Retrieved 11 April 2021.
  2. ^ INFORM.KZ (31 March 2021). "Vaccination with homegrown QazVac vaccine likely to start in late April". www.inform.kz. Retrieved 11 April 2021.
  3. ^ Yergaliyeva A (20 December 2020). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. Retrieved 2 March 2021.
  4. ^ Clinical trial number NCT04691908 for "Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
  5. ^ "Kazakh Biosafety Research Institute Begins Clinical Trials of Another Vaccine Against COVID-19". The Astana Times.
  6. ^ INFORM.KZ (26 April 2021). "Health Minister Alexei Tsoi to be one of the first to get homegrown QazCovid-in vaccine". www.inform.kz. Retrieved 26 April 2021.
  7. ^ It's unclear at which level of preparation the vaccine will be sent to Turkey.
  8. ^ MENAFN. "Kazakh COVID-19 vaccine to be bottled in Turkey". menafn.com. Retrieved 11 April 2021.
  9. ^ "QazVac готова и уже на подходе". Время (in Russian). Retrieved 11 April 2021.
  10. ^ "Kazakhstan Launches Production of First Homegrown Vaccine, 'QazVac'". caspiannews.com. Retrieved 26 April 2021.
  11. ^ INFORM.KZ (21 April 2021). "Healthcare Ministry comments on production of QazVac vaccine". www.inform.kz. Retrieved 22 April 2021.
  12. ^ "К концу апреля в Казахстане будет выпущено 50000 доз собственной вакцины". "СНГ СЕГОДНЯ" - последние новости стран СНГ читайте на SNG.TODAY. Retrieved 12 April 2021.
  13. ^ "Kazakhstan's COVID-19 vaccine to be bottled in Turkey". www.aa.com.tr. Retrieved 12 April 2021.
  14. ^ SATUBALDINA, ASSEL (5 October 2021). "Kazakhstan to Supply Its QazVac COVID-19 Vaccine to Other Countries Next Year". The Astana Times.
  15. ^ "Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. May 2021.
  16. ^ INFORM.KZ (31 March 2021). "Vaccination with homegrown QazVac vaccine likely to start in late April". www.inform.kz. Retrieved 11 April 2021.
  17. ^ "QazVac готова и уже на подходе". Время (in Russian). Retrieved 11 April 2021.
  18. ^ INFORM.KZ (9 April 2021). "3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15". www.inform.kz. Retrieved 11 April 2021.
  19. ^ "Kazakhstan's COVID-19 vaccine to be bottled in Turkey". www.aa.com.tr. Retrieved 11 April 2021.
  20. ^ tengrinews.kz (9 April 2021). "Как правильно применять казахстанскую вакцину QazVac, рассказал ученый". Главные новости Казахстана - Tengrinews.kz (in Russian). Retrieved 11 April 2021.
  21. ^ "QazVac готова и уже на подходе". Время (in Russian). Retrieved 11 April 2021.
  22. ^ Zakarya, Kunsulu; Kutumbetov, Lespek; Orynbayev, Mukhit; Abduraimov, Yergali; Sultankulova, Kulyaisan; Kassenov, Markhabat; Sarsenbayeva, Gulbanu; Kulmagambetov, Ilyas; Davlyatshin, Timur; Sergeeva, Maria; Stukova, Marina (1 September 2021). "Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan". EClinicalMedicine. 39: 101078. doi:10.1016/j.eclinm.2021.101078. ISSN 2589-5370. PMC 8363482.
  23. ^ "Казахстанскую вакцину QazVac будут разливать в Турции". informburo.kz (in Russian). 9 April 2021. Retrieved 12 April 2021.

External links

This page is based on the copyrighted Wikipedia article: QazCovid-in. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.